StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.47−0.37 (-3.76%)

Close on Nov 18, 2026Market cap $592.65MP/E –Yield –

Design Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Design Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $0. For fiscal 2025 it was $0.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0-100.0%
FY2020Dec 31, 2020$226.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0–
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2020Dec 31, 2020$33.00K–
Q3 FY2020Sep 30, 2020$20.00K–
Q2 FY2020Jun 30, 2020$31.00K–
Q1 FY2020Mar 31, 2020$142.00K–

More Design Therapeutics figures

See a number that looks wrong?